证券代码：000908 证券简称：ST景峰 公告编号：2025-063 湖南景峰医药股份有限公司 | 股东名称 | 持股数量 | 持股比例 | 累计被冻结 数量 | 占其所持股 | 占公司总股 | 冻结类型 | | --- | --- | --- | --- | --- | --- | --- | | | （股） | | （股） | 份比例 | 本比例 | | | 叶湘武 | 120,902,286 | 13.74% | 2,772,286 | 2.29% | 0.32% | 司法冻结 | | | | | 45,839,242 | 37.91% | 5.21% | 司法再冻结 | | | 合计 | | 48,611,528 | 40.21% | 5.53% | | 注：上表中累计司法再冻结股份均处于质押状态。 关于控股股东部分股份被冻结的公告 序号 股东 名称 是否为控 股股东或 第一大股 东及其一 致行动人 本次冻结股 份数量 （股） 占其 所持 股份 比例 占公司 总股本 比例 冻结 股份 是否 为限 售股 冻结 起始 日 冻结 到期 日 冻结 申请 人 冻结 类型 1 叶湘 武 是 19,839,242 ...

5、本次会议的通知、召集、召开、审议、表决程序均符合法律、行政法规、部 门规章、规范性文件和《公司章程》的规定，会议形成的决议合法、有效。 证券代码：000908 证券简称：ST景峰 公告编号：2025-061 湖南景峰医药股份有限公司 第八届董事会第四十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、湖南景峰医药股份有限公司（以下简称"公司"）于2025年7月15日以电子 邮件、电话、即时通讯等方式发出了关于召开第八届董事会第四十次会议的通知。 2、公司第八届董事会第四十次会议于2025年7月21日上午9:30-11:30以通讯方 式召开。 3、会议应参加表决董事9人，实际参与表决董事9人。 4、会议由代行董事长张莉女士主持，公司监事及高级管理人员列席了会议。 湖南景峰医药股份有限公司董事会 2025年7月22日 二、董事会会议审议情况 经审议，参会董事通过了以下议案： 1、《关于出售子公司股权的议案》。 为优化资产结构，公司拟将子公司上海景峰制药有限公司持有的江西延华医药 有限公司51%股权以人民币14.25万元 ...

ST景峰（000908）公告，公司拟将子公司上海景峰制药有限公司持有的江西延华医药有限公司51%股权 以人民币14.25万元的价格转让给江西少阳医药有限公司。本次交易完成后，江西延华将不再纳入公司 合并报表范围。本次交易标的2024年度营业收入为4357.59万元，占公司最近一个会计年度经审计营业 收入的10.47%。 ...

Market Performance - As of July 21, the Shanghai Composite Index rose by 0.72%, closing at 3559.7912 points [1] - The Shenzhen Component Index increased by 0.86%, closing at 11007.487 points [1] Top Gainers in Hunan Stocks - Boyun New Materials opened at 7.910 and closed at 8.700, with a daily increase of 9.99% and a trading volume of 913,006 shares [2] - Yipuli opened at 14.100 and closed at 14.100, with a daily increase of 9.98% and a trading volume of 73,411 shares [2] - Shanhe Intelligent opened at 8.310 and closed at 8.820, with a daily increase of 9.98% and a trading volume of 967,465 shares [2] - Zhejiang Construction Investment opened at 9.210 and closed at 9.620, with a daily increase of 6.65% and a trading volume of 798,714 shares [2] - Changgao Electric New opened at 7.450 and closed at 7.680, with a daily increase of 6.37% and a trading volume of 779,409 shares [2] Top Losers in Hunan Stocks - Hengli Retreat opened at 0.160 and closed at 0.150, with a daily decrease of 11.76% and a trading volume of 611,606 shares [3] - Qidi Pharmaceutical opened at 12.430 and closed at 12.120, with a daily decrease of 2.96% and a trading volume of 173,563 shares [3] - Yueyang Xingchang opened at 18.080 and closed at 17.610, with a daily decrease of 2.87% and a trading volume of 122,456 shares [3] - ST Jiajia opened at 6.180 and closed at 6.060, with a daily decrease of 1.78% and a trading volume of 73,498 shares [3] - ST Jingfeng opened at 5.830 and closed at 5.760, with a daily decrease of 1.37% and a trading volume of 119,258 shares [3]

Summary of Key Points Core Viewpoint - The company, Hunan Jingfeng Pharmaceutical Co., Ltd., disclosed its cumulative litigation and arbitration matters over the past twelve months, revealing a total amount involved of RMB 19.5736 million, which exceeds 10% of the company's latest audited net assets, thus meeting disclosure standards [1][2]. Group 1: Litigation and Arbitration Overview - The total amount involved in litigation and arbitration matters for the company and its subsidiaries is RMB 19.5736 million, with no single case exceeding RMB 10% of the latest audited net assets [1]. - There are no undisclosed litigation or arbitration matters that should have been reported [1]. Group 2: Potential Impact on Profit - The company will actively pursue legal actions to protect its rights and recover related funds, while also responding to cases where it is a defendant [2]. - The impact of these litigation matters on the company's current and future profits remains uncertain, as some cases are still pending trial or resolution [2].

一、累计诉讼、仲裁事项的基本情况 截至本公告披露日，除已披露的重大诉讼、仲裁事项外，公司及控股子公司 连续十二个月内累计发生的诉讼、仲裁事项的涉案金额共计人民币 1,957.36 万 元，涉案金额超过 1,000 万元，且占公司最近一期经审计净资产绝对值 10%以上， 达到披露标准，具体情况详见附件《公司累计诉讼、仲裁案件情况统计表》。 本次披露的诉讼、仲裁案件情况中，公司及控股子公司不存在单项涉案金额 占公司最近一期经审计净资产绝对值 10%以上，且绝对金额超过人民币 1,000 万 元的重大诉讼、仲裁事项。 证券代码：000908 证券简称：ST景峰 公告编号：2025-060 湖南景峰医药股份有限公司 关于累计诉讼、仲裁案件情况的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 湖南景峰医药股份有限公司（以下简称"公司"或"景峰医药"）根据《深 圳证券交易所股票上市规则》有关规定，对公司及控股子公司连续十二个月累计 涉及诉讼、仲裁事项进行了统计，现将有关统计情况公告如下： 特此公告 湖南景峰医药股份有限公司董事会 2025 年 7 月 18 日 二、其 ...

Core Viewpoint - The company, Hunan Jingfeng Pharmaceutical Co., Ltd., announces that part of the shares held by its controlling shareholder, Ye Xiangwu, will be subject to judicial enforcement due to a loan default, which will not affect the company's governance structure or operational status [1][3]. Group 1: Shareholder Information - Ye Xiangwu holds 120,902,286 shares, representing 13.74% of the company's total share capital [2]. - A total of 8,750,000 shares, accounting for 0.99% of the total share capital, will be disposed of through centralized bidding [1][2]. - The shares subject to enforcement are part of a pledge related to overdue loans provided as collateral to the Industrial and Commercial Bank of China [2][3]. Group 2: Judicial Enforcement Details - The enforcement period is set from July 22, 2025, to October 21, 2025 [1]. - The enforcement is based on a civil judgment that has already taken legal effect, concerning a financial loan dispute involving multiple parties, including the company and its subsidiaries [2][3]. - The company confirms that this share change does not violate any previously disclosed commitments or intentions [3]. Group 3: Company Governance and Compliance - The company assures that the judicial enforcement will not lead to a change in actual control or affect its production and operations [3]. - The board of directors will monitor the situation closely and ensure compliance with relevant laws and regulations during the enforcement period [4].

证券代码：000908 证券简称：ST 景峰 公告编号：2025-059 湖南景峰医药股份有限公司 关于控股股东所持部分公司股份将被司法强制执行的提示 性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、持有湖南景峰医药股份有限公司（以下简称"公司"或"景峰医药"） 120,902,286 股（约占公司总股本的 13.74%）的控股股东叶湘武先生收到《贵州 省贵阳市云岩区人民法院通知书》【（2024）黔 0103 执恢 705 号】，申请人中 国工商银行股份有限公司贵阳云岩支行申请通过集中竞价交易方式处置叶湘武 先生持有本案质押物的"ST 景峰"股份 875 万股，占公司总股本的比例为 0.99%。 2、叶湘武先生因被司法强制执行，将自 2025 年 7 月 22 日起的 3 个月内以 集中竞价交易方式被动减少公司股份 875 万股(约占公司总股本的 0.99%)。本次 强制执行期间为 2025 年 7 月 22 日至 2025 年 10 月 21 日。 3、叶湘武先生是公司的控股股东，本次股份变动不会导致公司实际控制权 发生变化，不会对公 ...

证券代码：000908 证券简称：ST景峰 公告编号：2025-058 湖南景峰医药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 （一）业绩预告期间：2025 年 1 月 1 日至 2025 年 6 月 30 日 （二）业绩预告情况：预计净利润为负值 项 目 本报告期 上年同期 归属于上市公司股东 亏损：3,000 万元至 4,500 万元 亏损：3,305.18 万元 的净利润 扣除非经常性损益后 亏损：2,700 万元至 4,050 万元 亏损：2,650.05 万元 的净利润 基本每股收益 亏损：0.0340 元/股至 0.0510 元/股 亏损：0.0376 元/股 营业收入 15,000 万元至 19,000 万元 20,257.81 万元 扣除后营业收入 15,000 万元至 19,000 万元 20,257.81 万元 注：上述表格中，扣除后营业收入指扣除与主营业务无关的业务收入和不具备商业实质 的收入后的营业收入。 二、与会计师事务所沟通情况 本次业绩预告的相关财务数据未经会计师事务所审计。 三、业绩变动原 ...

Company Overview - Hunan Jingfeng Pharmaceutical Co., Ltd. specializes in the research, manufacturing, and sales of pharmaceutical products, with key products including various injections and capsules that are unique or under national medical insurance categories [2]. Financial Performance - In Q1 2025, the company reported revenue of 100 million yuan, a year-on-year decrease of 0.46%, and a net loss of approximately 11.90 million yuan, reflecting a significant year-on-year decline of 960.04%. The gross profit margin stood at 66.62% [3]. Market Position - As of July 8, 2023, ST Jingfeng's stock closed at 5.99 yuan, with a rolling price-to-earnings (PE) ratio of 37.24 times, compared to the industry average PE of 54.20 times and a median of 32.89 times, placing the company at the 95th position within its industry [1][3]. - The total market capitalization of ST Jingfeng is 5.27 billion yuan [1]. Shareholder Information - As of March 31, 2025, the number of shareholders for ST Jingfeng was 34,311, a decrease of 6,228 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1].